Showing results for:
Carfilzomib is indicated in combination withLenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. It is also indicated as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.In a clinical study of relapsed multiple myeloma, carfilzomib and dexamethasone kept the disease from getting worse longer than bortezomib and dexamethasone (median of 18.7 months compared with 9.4 months) and helped patients live longer (median of 47.6 months compared with 40 months).Daratumumab (Darzalex®) plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three previous lines of therapy.
Kyprolis® Carfilzomib
Palifermin is FDA approved to help prevent or lessen severe oral mucositis (inflammation of the mucous membrane of the mouth) in patients receiving certain types of blood cancer therapy.
Kepivance® Palifermin
Pembrolizumab is FDA approved for the treatment of:Adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL)Pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapyAdult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy.Limitation of Use: Pembrolizumab is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Keytruda® Pembrolizumab
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment ofPatients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.Limitation of Use: Kymriah is not indicated for treatment of patients with primary central nervous system lymphomaAdult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Kymriah® Tisagenlecleucel